Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

 
• By Emily Hayes

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Businessman going straight ahead on a red carpet arrow between two maze

More from R&D

More from Scrip